'Mycosis fungoides' presentation slideshows

HANDOUT 1

HANDOUT 1. (INTRODUCTION) T-CELL INFILTRATES. CUTANOEUS LYMPHOID INFILTRATES COMMONLY ASKED QUESTIONS. 1. Is it benign or malignant? Distinguishing benign from neoplastic lymphoid infiltrates in the skin What sort of lymphoma is this? Problems with existing classifications

607 views • 53 slides

Spectrum of kidney diseases in malignancy

Spectrum of kidney diseases in malignancy. Ayman El-Sebaie, MRCP(UK) Head of Nephrology Dept., IMC. INTRODUCTION. Patients with malignancy are particularly vulnerable to development of renal abnormalities.

536 views • 42 slides

Case presentation

376 views • 27 slides

421 views • 25 slides

1 Coiffier B et al. J Clin Oncol 2012;30(6):631-6 . Proc ASH 2011;Abstract 591.

Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL) 2.

388 views • 17 slides

Hematopoietic Database and Manual

Hematopoietic Database and Manual. Changes made in 2014. Starting in 2014, there will be only one Hematopoietic Database. It will cover all of the hematopoietic diseases diagnosed from Jan. 1, 2010 forward.

321 views • 17 slides

Hematopoietic Database and Manual

Hematopoietic Database and Manual. Changes made in 2014. Starting in 2014, there will be only one Hematopoietic Database. It will cover all of the hematopoietic diseases diagnosed from Jan. 1, 2010 forward.

175 views • 17 slides

T-cell lymphoma

973 views • 14 slides

Krathen M et al. Proc ASH 2012; Abstract 797.

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. Krathen M et al. Proc ASH 2012; Abstract 797. Background.

276 views • 11 slides

Mycosis Fungoides Market: Industry Size, Trends & Forecast by Credence Research 2019-2027

The global market for mycosis fungoides is expected to expand from 2019 to 2027 at a CAGR of 4.9 percent. (According to a research study recently published by Credence Research".)

37 views • 3 slides